Superworth

Elicio Therapeutics revenue ELTX

Sales by quarter and over the last twelve months, from 2020.

Last 12 months, to Mar 31, 2023
$653K
Latest quarter, Q1 FY23
$0
−100% on a year earlier
Fiscal year 2022
$2.3M
−92% on the year before

Elicio Therapeutics' revenue was $653K over the twelve months to Mar 31, 2023, down 98% on a year earlier.

In its latest quarter, Q1 FY23, it was $0, down 100% on the same quarter a year before.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2022$2.3M−92%
FY2021$28.3M+883%
FY2020$2.9Mn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q1 FY23$0−100%$653K
Q4 FY22$0−100%$2.3M
Q3 FY22$0−100%$28.2M
Q2 FY22$653K+21%$29.7M
Q1 FY22$1.6M+344%$29.6M
Q4 FY21$25.9M+5552%$28.3M
Q3 FY21$1.5M+77%$2.8M
Q2 FY21$540K−26%$2.2M
Q1 FY21$371K−57%$2.4M
Q4 FY20$459Kn/a$2.9M
Q3 FY20$827Kn/an/a
Q2 FY20$729Kn/an/a

Against its peers

Companies in Drug Manufacturers - General nearest Elicio Therapeutics' size, closest first, today.

CompanyRevenue, 12 monthsGrowth
ELTXElicio Therapeuticsn/m
ATNMActinium Pharmaceuticalsn/m
SPROSpero Therapeutics$47M−3% a year
LFVNLifevantage$182.6M−20% a year
NATRNatures Sunshine Products$492M+7% a year
ARVNArvinas$316.7M−15% a year
Peer median$249.6M

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Elicio Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.